Macular disease

Melbourne biopharmaceutical company Opthea has received an $8.5 million research and development (R&D) tax credit from the Australian tax authority...

Australian of the Year and ophthalmologist Dr James Muecke has endorsed a new campaign aimed at motivating Australians in their...

Australian researchers are using genetic testing to identify as many people as possible with inherited retinal disease (IRD), in preparation...

For 40 years laser therapy has been the standard treatment for proliferative diabetic retinopathy (PDR), but now Australian ophthalmologists have...

A US company that has incorporated dark adaptometry into a new wearable headset for age-related macular degeneration (AMD) is on...

In a historical development for the eye health sector, the Therapeutics Goods Administration (TGA) has approved the country’s first true...

A biopharmaceutical company that is developing cheaper anti-VEGF treatments for Australia and other markets has launched a global clinical trial...

Melbourne biopharmaceutical company Opthea has announced its inclusion on the ASX 300, just days after its lead drug candidate met...

A biopharmaceutical company that is developing cheaper anti-VEGF treatments for major global markets, including Australia, has reported positive results from...

Macular Disease Foundation Australia (MDFA) has launched a series of community service announcements featuring national icon Ms Ita Buttrose in...